1. Home
  2. FT vs ACIU Comparison

FT vs ACIU Comparison

Compare FT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

N/A

Current Price

$7.84

Market Cap

202.6M

Sector

Finance

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.91

Market Cap

213.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FT
ACIU
Founded
1988
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.6M
213.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
FT
ACIU
Price
$7.84
$2.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
63.0K
1.4M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,482,957.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$738.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$1.43
52 Week High
$7.23
$4.00

Technical Indicators

Market Signals
Indicator
FT
ACIU
Relative Strength Index (RSI) 36.80 47.78
Support Level $7.79 $2.54
Resistance Level $7.91 $3.45
Average True Range (ATR) 0.10 0.30
MACD -0.02 0.04
Stochastic Oscillator 12.50 31.75

Price Performance

Historical Comparison
FT
ACIU

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: